Navigation Links
MERIAL Receives Full License Approval for ONCEPT(TM) Canine Melanoma Vaccine
Date:2/16/2010

DULUTH, Ga., Feb. 16 /PRNewswire/ -- Merial, a world-leading animal health company, has gained full-licensure from the U.S. Department of Agriculture for ONCEPT™ Canine Melanoma Vaccine, DNA.  ONCEPT is a breakthrough vaccine indicated for aiding in extending survival of dogs with stage II or stage III oral canine melanoma, a common yet deadly form of cancer in dogs.

ONCEPT is the first and only USDA-approved, therapeutic vaccine for the treatment of cancer – in either animals or humans.

Traditionally, dogs with stage II or stage III malignant melanoma survive less than five to six months when treated with surgery alone.(1) Clinical studies of ONCEPT demonstrated significantly longer life spans even in dogs with stage II or stage III of oral melanoma.  In fact, median survival time of dogs treated with ONCEPT could not be determined because more than 50 percent of the treated dogs were still living melanoma-free at the conclusion of the study or died of unrelated illness.(2)

Canine oral melanoma is a common type of cancer in dogs and is the most common malignant tumor of the dog's mouth. It can also be seen in the nail and footpad.(3) Canine melanoma may be seen in any breed and is a highly aggressive cancer that frequently spreads throughout the body, including the lymph nodes, liver, lungs and kidneys.(4) To date, the most common treatments for this form of cancer have been radiation and surgery to establish local tumor control. Canine oral melanoma, however, has a high propensity to metastasize to other parts of the body and is often resistant to chemotherapy.(2,3)

"Canine melanoma spreads readily, and, unfortunately, existing treatments have not succeeded in controlling the disease," said Dr. Bob Menardi, a veterinarian and spokesperson for Merial. "ONCEPT is a new adjunct
'/>"/>

SOURCE Merial
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Merial invests US $70 million in Nanchang, China
2. Abbott Receives U.S. FDA Approval for Heat-Stable Norvir(R) (ritonavir) Tablets
3. Simcere Receives SFDA Approval to Manufacture and Sell Zanamivir in China
4. Candela Receives Registration Approval to Market Its Best-in-Class GentleMax and Alex TriVantage Lasers in China
5. Avrio Receives Drug Manufacturing License and Medical Device Manufacturing License from the California Food and Drug Branch
6. Volcano Receives FDA Clearance to Market the Eagle Eye(R) Platinum Digital IVUS Catheter
7. InteKrin Therapeutics Co-Founder Receives Appointment as Professor of Medicine at Harvard Medical School
8. Novus Scientific Receives FDA Clearance for TIGR(TM) Matrix Surgical Mesh - Worlds 1st Long-Term Resorbable Synthetic Mesh
9. Lillys Online, Interactive Health Education Program Receives Two Web Awards
10. Repligen Receives Notice of Allowance for Recombinant Protein A Patent
11. INNOPHARMA Receives First FDA Approval
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... , Sept. 22, 2014  AbbVie (NYSE: ... clinical studies evaluating potential new medicines in the ... upcoming 2014 European Society of Medical Oncology (ESMO) ... Spain . Data being presented include results ... and efficacy of veliparib (ABT-888), a poly (adenosine ...
(Date:9/22/2014)... BRIDGEWATER, N.J. , Sept. 22, 2014 /PRNewswire/ ... focused on developing and commercializing therapeutic products for ... disease, today is pleased to announce that TUV-SUD ... the Netherlands (MEB) has granted its ... catheter lock solution.  Neutrolin was initially approved in ...
(Date:9/22/2014)... and NEW YORK , ... (OTCBB: ACCP), has signed an exclusive, global license ... development and commercialization of its proprietary plasma fractionation ... management team and its intention to strategically refocus ... and its plans to pursue a national listing ...
Breaking Medicine Technology:AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 2AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 3AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 4Neutrolin Label Expansion Approved for the European Union 2Neutrolin Label Expansion Approved for the European Union 3Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 2Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 3Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 4Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 5Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 6
... SILVER SPRING, Md., March 25, 2011 The U.S. Food ... patients with late-stage (metastatic) melanoma, the most dangerous type ... ) Melanoma is the leading cause ... cases of melanoma were diagnosed in the United States ...
... CoreLab Partners, Inc , the global entity resulting ... is set to attend and actively participate in several ... two weeks. "The legacy of our organization ... physicians, scientists and operational personnel have provided to the ...
Cached Medicine Technology:FDA Approves New Treatment for a Type of Late-Stage Skin Cancer 2FDA Approves New Treatment for a Type of Late-Stage Skin Cancer 3CoreLab Partners Collaborates at Worldwide Industry Conferences 2
(Date:9/22/2014)... 2014 PreDiabetes Centers , a ... with companies to help employees learn their risk for ... as part of a collaboration with the American Diabetes ... , PreDiabetes Centers Medical Director Alan Hopkins, MD, ... Austin on Tuesday, October 21st to discuss the epidemic ...
(Date:9/22/2014)... Steven Reinberg HealthDay Reporter ... have known that bacterial pneumonia can raise your risk of ... actually invade and kill heart cells, increasing the chances of ... scientists report. In mice, monkeys and human heart ... the bacteria, and they tried a vaccine that might one ...
(Date:9/22/2014)... 2014 At the 10th Clinton ... Nutrition Partnership (SNP) announced the successful launch of ... Cardiovascular Risk Reduction Program for Women. The announcement ... mitigate their risk of heart disease through a ... plan for addressing significant global challenges made by ...
(Date:9/22/2014)... 2014 TweetMyJobs, a global ... today an agreement with HealthcareSource, the leading ... healthcare industry. The agreement gives HealthcareSource clients ... recruiting solutions directly from within HealthcareSource Position ... healthcare organizations. The partnership provides TweetMyJobs additional ...
(Date:9/22/2014)... MAINE AND BOSTON -- In a collaboration that ... advance cancer research and patient care and accelerate ... Beth Israel Deaconess Medical Center (BIDMC) have established ... institutions, presidents announced today. , A recently signed ... Center to establish a comprehensive relationship in the ...
Breaking Medicine News(10 mins):Health News:PreDiabetes Centers to Offer Diabetes Screening at Several Companies Around Austin 2Health News:PreDiabetes Centers to Offer Diabetes Screening at Several Companies Around Austin 3Health News:Scientists Spot How Bacterial Pneumonia Damages the Heart 2Health News:Scientists Spot How Bacterial Pneumonia Damages the Heart 3Health News:At 2014 Clinton Global Initiative Annual Meeting, Seafood Nutrition Partnership Announces Pilot Program to Reduce Women’s Heart Disease Risks 2Health News:At 2014 Clinton Global Initiative Annual Meeting, Seafood Nutrition Partnership Announces Pilot Program to Reduce Women’s Heart Disease Risks 3Health News:At 2014 Clinton Global Initiative Annual Meeting, Seafood Nutrition Partnership Announces Pilot Program to Reduce Women’s Heart Disease Risks 4Health News:TweetMyJobs and HealthcareSource Partner To Provide Social Recruiting Solutions to Healthcare Organizations 2Health News:TweetMyJobs and HealthcareSource Partner To Provide Social Recruiting Solutions to Healthcare Organizations 3Health News:TweetMyJobs and HealthcareSource Partner To Provide Social Recruiting Solutions to Healthcare Organizations 4Health News:The Jackson Laboratory and BIDMC announce multifaceted affiliation 2Health News:The Jackson Laboratory and BIDMC announce multifaceted affiliation 3
... could help prevent complications for pregnant women with the ... the 20th week of pregnancy and is characterized by ... the urine. In severe cases it can lead to ... the mother to suffer a series of potentially fatal ...
... embryo transfer instead of a double embryo transfer during ... births without substantially lowering live births, // according to ... than 36 and compared the two approaches of in ... at least one live birth and rates of multiple ...
... nearly 15 million people worldwide. Problems with a ... sneezing, laughing, or lifting heavy objects. Austrian researchers ... with their own stem cells, which they say ... involves removing stem cells from a patient's arm, ...
... that stem cell therapy is effective in treating pigs ... cells from one pig's bone marrow and injecting them ... heart's function to its original condition. ,Researchers studied ... and half of them received therapy. They found injecting ...
... According to a recent study researchers say autistic boys with ... suffering from a language-related disorder known as Specific Language Impairment ... specialists better understand autism and how to choose the best ... MRI scans to look at Broca’s area -- a key ...
... new study the healthiest environment for your child at bedtime ... at night may put children at risk for leukemia.// ... night workers and an increased risk for breast cancer, further ... factor for leukemia. ,Researchers have determined that light at ...
Cached Medicine News:
... for catheter or instrument introduction. The ... be peeled away and removed. The ... instrument to be introduced should be ... the sheath. Supplied sterile in peel-open ...
Used for antegrade placement of a safety wire guide prior to endourological procedures. Supplied sterile in peel-open packages. Intended for one-time use....
Used to establish a percutaneous tract into the renal pelvis for catheter placement or stone manipulation. Supplied sterile in peel-open packages. Intended for one-time use....
Used when establishing a percutaneous tract for nephrostomy drainage. The guide has a stiff shaft and a gradual transition to a very flexible distal tip. Supplied sterile in peel-open packages. Inten...
Medicine Products: